$10.720
-0.809 (-7.55%)Al cierre
Predicciones de precio
Ábrelo en la app para desbloquear previsiones a más largo plazo.
¿Debería comprar acciones de Retension Pharmaceuticals, Inc. Common Stock?
Retension Pharmaceuticals may not be a good buy right now due to its current price of $11.44, which is significantly below the analyst's target of $55, but the recent 5-day decline of 19.66% raises concerns about short-term performance. The company has reported negative net income in the last four quarters, with a loss of $4,170,589 in Q2 2026, indicating ongoing financial struggles.
RTSN cerró en $10.72 el Thursday, tras bajar -7.55%
Retension Pharmaceuticals, Inc. Common Stock (RTSN) last closed at $10.7200003, losing -7.55%. These facts feed the 1-day and 1-week RTSN price prediction above.
Factores de la previsión
Los factores de la previsión de Retension Pharmaceuticals, Inc. Common Stock (RTSN) combinan patrones gráficos similares, estacionalidad y medias móviles.
Seasonality
Bearish
Análisis de estacionalidad de RTSN
Artículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.